Adjuvant chemotherapy for colorectal cancer: age differences in factors influencing patients' treatment decisions

Abstract

PurposeOlder colorectal cancer patients are significantly less likely than younger patients to receive guideline-recommended adjuvant chemotherapy. Previous research has indicated that patient refusal of treatment is a contributing factor. This study aimed to identify potential barriers to adjuvant chemotherapy use in older patients by examining the associations between patient age, factors influencing chemotherapy treatment decisions, and preferences for information and decision-making involvement.Patients and methodsSixty-eight patients who underwent surgery for colorectal cancer in Sydney, Australia, within the previous 24 months completed a self-administered survey.ResultsFear of dying, health status, age, quality of life, and understanding treatment procedures and effects were significantly more important to older patients (aged ≥65 years) than younger patients in deciding whether to accept chemotherapy (all P < 0.05). Reducing the risk of cancer returning and physician trust were important factors for all patients. Practical barriers such as traveling for treatment and cost were rated lowest. Older patients preferred less information and involvement in treatment decision making than younger patients. However, 60% of the older group wanted detailed information about chemotherapy, and 83% wanted some involvement in decision making. Those preferring less information and involvement still rated many factors as important in their decision making, including understanding treatment procedures and effects.ConclusionA range of factors appears to influence patients’ chemotherapy decision making, including, but not limited to, survival benefits and treatment toxicity. For older patients, balancing the risks and benefits of treatment may be made more complex by the impact of emotional motivators, greater health concerns, and conflicts between their need for understanding and their information and decision-making preferences. Through greater understanding of perceived barriers to treatment and unique motivators for treatment choice, physicians may be better able to support older patients to make informed decisions about their care.

Survival Status and Predictors of Mortality Among Colorectal Cancer Patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A Retrospective Follow-up Study

“…With regards to age, the survival time of patients diagnosed with colorectal cancer in this study is lower than other study done in Netherlands [27]. The survival difference between young and older colorectal patients arises from different attributes of survival such as: difference in treatment modalities, the unfavorable effects of medication and intoxication, comorbidity in older patients, and low progression of disease in younger patients [28]. This could be due to lack of health awareness in receiving medical care, adherence to treatment during outpatient treatment and frequent follow-up constraint.…”

Chemotherapy Use and Survival Among Young and Middle-Aged Patients With Colon Cancer

“…A recent study on colorectal cancer chemotherapy, which had a small number of patients and no adjustment for potential confounders, showed that younger patients preferred more information about the disease and chemotherapy and wanted to be more involved in treatment decisions. 32 …”

Rising Incidence of Colorectal Cancer Among Young Hispanics in Texas

“…According to the TCR, five-year CSS among 20–39 year olds was, stage for stage, either comparable or superior to that of older age groups. Because younger cancer patients are, in general, more likely than older patients to receive aggressive antineoplastic therapy due to higher performance status, fewer comorbidities, and more willingness to accept risk, the superior survival among younger CRC patients in the TCR and other population-based studies may simply reflect selection bias rather than inherent tumor biology 38,39 . Indeed, a pooled analysis of 20,023 patients enrolled in randomized controlled trials for first-line stage IV CRC 40 revealed that, after adjustment for performance status and sex, the youngest patients (those near 18 years old) had inferior overall and progression-free survival when compared to middle-aged patients (those near 57 years old), especially during the first year of treatment.…”